H01 in Adults With Interstitial Lung Disease

hymecromone · Фаза 2

ID реестра
NCT06325696
Фаза
Фаза 2
Статус
Набор идет
Препарат / вмешательство
hymecromone
Спонсор
National Institute of Environmental Health Sciences (NIEHS)
Начало
2025-05-05
Набор участников
37
Центры
1

Об исследовании

Background: Interstitial lung disease affects the tissues that aid the transfer of oxygen and carbon dioxide between the air and the bloodstream. The disease can cause fibrosis, a thickening and scarring of lung tissue. Fibrosis often continues getting worse, and most people with this disease die in 3 to 5 years. Objective: To test a study drug (hymecromone) in people with interstitial lung disease or lung fibrosis. Eligibility: People aged 18 years and older with interstitial lung disease or lung fibrosis. Design: Participants will have at least 7 clinic visits over 5 months. Participants will have screening and baseline visits. They will have blood tests and tests of their heart function. They will give a sputum sample. Other tests will include: Spirometry: Participants will bre

Открыть NCT06325696 на ClinicalTrials.gov →

Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT06325696 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.